Drug Discovery for Coronary Artery Disease

Area of Science:

• Cardiology
• Pharmacology
• Drug Discovery

Background:

• Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality.
• Existing treatments like statins, PCSK9 inhibitors, and antithrombotics have reduced coronary artery disease (CAD) but residual risk remains high.
• CAD imposes a significant burden on healthcare systems worldwide.

Purpose of the Study:

• To review recently approved and investigational cardiovascular drugs.
• To focus on the pharmacology and limitations of these new therapeutic agents.
• To explore emerging areas in cardiovascular drug discovery, including inflammation and cardiac regeneration.

Main Methods:

• Literature review of approved and clinically developing cardiovascular drugs.
• Analysis of pharmacological mechanisms and clinical trial data.
• Discussion of novel therapeutic targets and approaches.

Main Results:

• New agents for cholesterol/triglyceride lowering offer potential for further cardiovascular risk reduction.
• Certain antidiabetic drugs demonstrate cardiovascular benefits in diabetic patients.
• Investigational antithrombotic agents aim to reduce bleeding risk.
• IL-1β antibody success highlights inflammation as a key therapeutic target.

Conclusions:

• Emerging cardiovascular drugs targeting lipids, inflammation, and diabetes show significant promise.
• Novel therapeutic strategies, including those targeting residual risk and exploring traditional medicine, are crucial for advancing CVD treatment.
• Continued research in human genetics and pathway elucidation will drive future cardiovascular drug discovery.